Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Cancer Treatment and Research Communications is Scopus-indexed (Q2, CiteScore 5), WoS ESCI, DOAJ. It is covered by India's One Nation One Subscription scheme for reading access. Published by Elsevier Ltd.
Checked against the index lists dated .
ISSN 2468-2942Verify ISSN ↗
Publisher: Elsevier Ltd
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 158 / 428 | 63rd | Q2 |
| Cancer Research | 128 / 233 | 45th | Q3 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2016–present, best quartile Q2, CiteScore 5.
Cancer Treatment and Research Communications is Q2 in Oncology (rank 158 of 428) and Q3 in Cancer Research (rank 128 of 233), by CiteScore 2025.
Cancer Treatment and Research Communications is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 5, which places it in quartile Q2 at the 63rd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.995, quartile Q2, with an H-index of 35.
The publisher lists an article processing charge of about US$2,740 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Cancer Treatment and Research Communications is published by Elsevier Ltd. Its ISSN is 2468-2942.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
Cancer Treatment and Research Communications has an h-index of 38 and a 2-year mean of 1.26 citations per paper (OpenAlex). Its Scopus CiteScore is 5, quartile Q2. On 2-year citations it ranks #265 of 424 Scopus journals in Oncology.
Cancer Treatment and Research Communications published 210 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2026), authors are most often from China (20.2%), Japan (10.1%) and United States (9%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 11 retracted papers are recorded (8 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.